Healthium is a global Medtech company that focuses on surgical, post-surgical and chronic care. The company holds a vision to make precision Medtech products accessible to every patient globally. Healthium Medtech has a huge product base related to its focus areas with over 52,000 SKUs.
The brand has an amazing commercial presence and market access in India and the UK. They export products to over 80 countries including the US, UK, Germany and France (developed markets and South America, Asia and America (developing markets). Their comprehensive portfolio of quality products at captivating value makes the company stand out from the competition.
Healthium Medtech IPO Objectives
Here are a few quick reasons why Healthium Medtech going public:
- The fund will be used to create awareness and visibility of the company among the existing and potential customers.
- Investment of the fund into the brand’s subsidiaries Sironix, Clinisupplies and Quality Needles.
Why should you invest in the Healthium Medtech IPO?
- In India, Healthcare is amongst the fastest-growing markets in terms of revenue.
- As per Frost & Sullivan analysis, during the year 2021-2025, the Indian healthcare market is expected to grow at a sarge of 13.9%.
Healthium Medtech Limited IPO consists of fresh issue of equity shares of Rs 390 Cr. Plus, with an offer of sale of up to 39.10 million shares by current shareholders and promoters. Healthium Medtech has established itself as the largest medical device company and the second-largest one in the surgical consumables market in India.
IPO Financials
| Particulars | 2021 | 2020 |
|---|---|---|
| Revenue from operations (₹ million) | 7,133.57 | 6,391.79 |
| Restated profit before tax (₹ million) | 1,130.33 | 578.81 |
| Restated profit for the year (₹ million) | 854.28 | 367.60 |
| Gross margin (%) | 62.33% | 65.89% |
| EBITDA (₹) | 1,539.27 | 955.74 |
| EBITDA margin (%) | 21.58% | 14.95% |
| ROE (%) | 21.57% | 10.98% |
| ROCE (%) | 22.98% | 16.08% |
| Cash conversion cycle (in days) | 139 | 171 |
| Net cash flow from operating activities (₹ million) | 1,221.29 | 589.24 |
| Net cash flows from/ (used in) operating activities / EBITDA (%) | 79.34% | 61.65% |
Know before investing
Strengths
3For the brand’s strong global reach, it is subjected to gain benefits from favorable industry dynamics in high growth market.
The company’s R&D department has a proven track record of amazingly commercialising the products.
The brand's strong presence in India and several other countries (UK, US, Europe, etc.) has created a strong market reach for them.
Risks
3Any health pandemic, social unrest, and natural disasters can affect the business adversely.
Any delay from the vendors can affect the business adversevely.
Inflation in India can adversely affect the business.
